Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

ClinicalTrials.gov ID: NCT01514149

Public ClinicalTrials.gov record NCT01514149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.

Study identification

NCT ID
NCT01514149
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ConjuChem
Industry
Enrollment
73 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2011 (Type not available)
Primary completion
May 2012 (Actual)
Completion
Mar 2013 (Actual)
Last update posted
Jul 19, 2017

2011 – 2013

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Research Site Phoenix Arizona 85018 —
Research Site Inglewood California 90301 —
Research Site Tarzana California 91356 —
Research Site Ventura California 93003 —
Research Site Wellington Florida 33414 —
Research Site Idaho Falls Idaho 83404 —
Research Site Lexington Kentucky 40504 —
Research Site Brighton Massachusetts 02135 —
Research Site Greensboro North Carolina 27405 —
Research Site Eugene Oregon 97401 —
Research Site Altoona Pennsylvania 16602 —
Research Site East Providence Rhode Island 02915 —
Research Site Charleston South Carolina 29407 —
Research Site Taylors South Carolina 29687 —
Research Site Austin Texas 78758 —
Research Site Dallas Texas 75231 —
Research Site San Antonio Texas 78249 —
Research Site Salt Lake City Utah 84107 —
Research Site Henrico Virginia 23233 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01514149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 19, 2017 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01514149 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →